How do you build a EUR 200 million venture fund from scratch? At BioStock Life Science Summit 2026, Thomas Thestrup, founding Managing Director of Fresenius Ventures, the venture arm recently launched by the global healthcare group Fresenius, took to the stage to answer exactly that.
In conversation with BioStock’s Jonas Söderström, Thestrup described the fund’s strategy and what he looks for in future investments. Backed by one of the world’s leading healthcare groups, Fresenius Ventures can offer start-ups more than capital, including industry expertise, networks and a route to market.
Thestrup has more than 15 years of experience across research, biotech, healthtech and pharma. He began his investment career at Sunstone Life Science Ventures, held senior business development roles at UCB Pharma and Lundbeck, and joined Fresenius from Angelini Ventures.
See the full interview “Strategic Money: Building a €200m Venture Fund From Scratch” below.
